Boothbay Fund Management LLC Buys Shares of 138,963 Dianthus Therapeutics, Inc. $DNTH

Boothbay Fund Management LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 138,963 shares of the company’s stock, valued at approximately $5,468,000. Boothbay Fund Management LLC owned approximately 0.32% of Dianthus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. Braidwell LP acquired a new stake in shares of Dianthus Therapeutics during the third quarter valued at $32,859,000. Marshall Wace LLP purchased a new stake in Dianthus Therapeutics during the 3rd quarter worth about $22,545,000. Finally, Franklin Resources Inc. purchased a new stake in Dianthus Therapeutics during the 3rd quarter worth about $17,720,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research report on Monday, March 9th. Raymond James Financial raised shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the company from $63.00 to $123.00 in a research note on Tuesday, March 10th. Robert W. Baird raised their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Finally, Wedbush lifted their target price on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $115.33.

Insider Activity at Dianthus Therapeutics

In related news, CEO Marino Garcia sold 122,918 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Simrat Randhawa sold 33,830 shares of Dianthus Therapeutics stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 200,430 shares of company stock valued at $16,332,702. Corporate insiders own 16.56% of the company’s stock.

Dianthus Therapeutics Stock Down 3.1%

NASDAQ DNTH opened at $77.86 on Monday. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.36 and a fifty-two week high of $88.02. The business has a 50 day moving average price of $52.53 and a two-hundred day moving average price of $42.82. The stock has a market cap of $3.46 billion, a PE ratio of -18.99 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.